News | June 15, 2021
JB Chemicals PAT jumps by 101% to Rs101 Cr
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
Dozee plans to further tap over 2,000 hospitals in more than 100 districts
Subscribe To Our Newsletter & Stay Updated
